But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
